Cargando…
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial
IMPORTANCE: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the...
Autores principales: | Teng, Edmond, Manser, Paul T., Pickthorn, Karen, Brunstein, Flavia, Blendstrup, Mira, Sanabria Bohorquez, Sandra, Wildsmith, Kristin R., Toth, Bali, Dolton, Michael, Ramakrishnan, Vidya, Bobbala, Ashwini, Sikkes, Sietske A. M., Ward, Michael, Fuji, Reina N., Kerchner, Geoffrey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194753/ https://www.ncbi.nlm.nih.gov/pubmed/35696185 http://dx.doi.org/10.1001/jamaneurol.2022.1375 |
Ejemplares similares
-
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
por: Monteiro, Cecilia, et al.
Publicado: (2023) -
Cross‐sectional and longitudinal assessments of function in prodromal‐to‐mild Alzheimer's disease: A comparison of the ADCS‐ADL and A‐IADL‐Q scales
por: Teng, Edmond, et al.
Publicado: (2023) -
Baseline [(18)F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
por: Teng, Edmond, et al.
Publicado: (2021) -
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
por: Jamalian, Samira, et al.
Publicado: (2023) -
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
por: Barthélemy, Nicolas R., et al.
Publicado: (2022)